Novogen Limited (NASDAQ:KZIA) Receives Average Rating of “Moderate Buy” from Analysts

Novogen Limited (NASDAQ:KZIA) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $27.3333.

KZIA has been the topic of a number of recent research reports. BTIG Research reissued a “buy” rating and set a $40.00 target price on shares of Novogen in a research report on Thursday, September 10th. Canaccord Genuity Group started coverage on shares of Novogen in a research note on Thursday, August 13th. They set a “buy” rating and a $29.00 price target on the stock. Lake Street Capital started coverage on shares of Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research report on Friday, July 17th.

Novogen Price Performance

Novogen stock opened at $10.39 on Friday. Novogen has a one year low of $4.86 and a one year high of $17.40. The stock’s 50 day moving average price is $12.86 and its 200 day moving average price is $11.79.

About Novogen

Novogen Limited, now known as Kazia Therapeutics Limited, is an Australia-based biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on targeted treatments designed to address tumors that are difficult to treat with conventional approaches.

Kazia’s principal clinical program has been paxalisib, an orally administered inhibitor of the PI3K/mTOR pathway being investigated primarily for brain cancers, including glioblastoma.